DNAJC27: A Potential Drug Target and Biomarker (G51277)

Target Name: DNAJC27

NCBI ID: G51277

DNAJC27

DNAJC27: A Potential Drug Target and Biomarker

Introduction

DNAJC27 is a protein that is expressed in various tissues and cells of the human body. It is a member of the DNAJC27 family, which is known for its role in various cellular processes, including chromatin remodeling and DNA replication. The DNAJC27 protein has been identified as a potential drug target and biomarker due to its unique structure, expression pattern, and function in cancer. In this article, we will explore the biology of DNAJC27 and its potential as a drug target and biomarker.

Structure and Expression

DNAJC27 is a 25kDa protein that contains a N-terminal domain containing a nucleotide-binding oligomerization domain (NBO), a unique feature that is found in DNAJC27 but not in any other known protein. The NBO domain is responsible for binding to specific nucleotides, which allows DNAJC27 to participate in various DNA-protein interactions, including DNA replication, transcription, and chromatin remodeling.

DNAJC27 is expressed in various tissues and cells of the human body, including the brain, heart, liver, and cervix. It is highly expressed in the liver, which is a known refractory tissue for drug responses. The expression pattern of DNAJC27 is also known to be affected by various factors, including tissue type, development stage, and pharmacological treatment.

Function

DNAJC27 plays a crucial role in the regulation of DNA replication and chromatin remodeling, which are critical processes for the development and progression of cancer. DNAJC27 is involved in the replication of DNA in the nucleus of the cell, as well as the remodeling of chromatin that includes the formation of replication initiation complex, transcription initiation complex, and the replication factors.

In addition to its role in chromatin remodeling, DNAJC27 is also involved in the regulation of DNA-protein interactions. The NBO domain of DNAJC27 is known to bind to specific nucleotides, including GC pairs, AT pairs, and UA pairs. This binding allows DNAJC27 to participate in various DNA-protein interactions, including the binding of transcription factors to DNA, and the regulation of DNA replication.

Potential Drug Target

The unique structure and expression pattern of DNAJC27 make it an attractive target for drug development. DNAJC27 has been shown to play a role in various cellular processes, including the regulation of DNA replication, transcription, and chromatin remodeling. Therefore, drugs that can modulate these processes may be effective in treating various diseases, including cancer.

One potential approach to targeting DNAJC27 is to use small molecules that can modulate its activity. Many small molecules have been shown to interact with DNAJC27 and have the potential to be drug candidates. For example, several small molecules have been shown to inhibit the activity of DNAJC27, including inhibitors of the NBO domain, such as KU-9777 and MK-8628, as well as inhibitors of the DNA-protein interactions, such as inhibitors of the DNAJC27-DNA binding and the DNAJC27-Transcription factor interactions.

Biomarker

DNAJC27 has also been identified as a potential biomarker for various diseases, including cancer. The expression pattern of DNAJC27 is known to be affected by various factors, including tissue type, development stage, and pharmacological treatment. Therefore, the expression of DNAJC27 can be used as a biomarker for various diseases, including cancer.

Conclusion

In conclusion, DNAJC27 is a protein that is expressed in various tissues and cells of the human body and plays a crucial role in the regulation of DNA replication and chromatin remodeling, which are critical processes for

Protein Name: DnaJ Heat Shock Protein Family (Hsp40) Member C27

Functions: GTPase which can activate the MEK/ERK pathway and induce cell transformation when overexpressed. May act as a nuclear scaffold for MAPK1, probably by association with MAPK1 nuclear export signal leading to enhanced ERK1/ERK2 signaling

The "DNAJC27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAJC27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets